OBJECTIVES: To report our experience with the first 230 cases of holmium laser enucleation of the prostate (HoLEP) performed in a single center. METHODS: A total of 230 cases of HoLEP were performed between June 2007 and June 2008. Mean age of patients was 69.8 +/- 10.3 years, and 21.3% of patients were either on anticoagulant or antiplatelet treatment. There was no limit for prostate size, with a mean prostate size of 86.5 +/- 65.4 g (range: 20-350 g). Follow-up was performed regularly at 1, 3, 6, and 12 months, assessing the Q(max), PVR, and International Prostate Symptom Score. RESULTS: Weight of prostate chips retrieved after morcellation was 78.6 +/- 61.3 g (range: 10-350), with enucleation time 102.2 +/- 55.4 minutes and morcellation time 19.3 +/- 10.1 minutes, leading an estimated efficiency rate of 0.64 g/min. The rate of decrease in prostate volume and prostate-specific antigen was 90.8% and 82.5%, respectively. At 1 month, mean Q(max) increased from 7.7 +/- 2.3 to 25.8 +/- 10.1 mL/s (P <or=.001), mean PVR decreased from 171.3 +/- 126.3 to 41.6 +/- 45.7 mL (P <or=.001), and mean international prostate symptom score improved from 17.3 +/- 6.7 to 6.6 +/- 3.4 (P <or=.001). These improvements were sustained throughout a 12-month follow-up period. Temporary irritative symptoms were evident in 34.6% and stress urinary incontinence in 9%, both of which were self-limited on medical treatment and Kegel exercises, respectively. Only 1 patient with pancytopenia required blood transfusion and there was no case for transurethral resection syndrome. CONCLUSIONS: HoLEP is a safe and an effective modern modality for the treatment of symptomatic BPH regardless of the gland size, with satisfactory clinical outcome. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVES: To report our experience with the first 230 cases of holmium laser enucleation of the prostate (HoLEP) performed in a single center. METHODS: A total of 230 cases of HoLEP were performed between June 2007 and June 2008. Mean age of patients was 69.8 +/- 10.3 years, and 21.3% of patients were either on anticoagulant or antiplatelet treatment. There was no limit for prostate size, with a mean prostate size of 86.5 +/- 65.4 g (range: 20-350 g). Follow-up was performed regularly at 1, 3, 6, and 12 months, assessing the Q(max), PVR, and International Prostate Symptom Score. RESULTS: Weight of prostate chips retrieved after morcellation was 78.6 +/- 61.3 g (range: 10-350), with enucleation time 102.2 +/- 55.4 minutes and morcellation time 19.3 +/- 10.1 minutes, leading an estimated efficiency rate of 0.64 g/min. The rate of decrease in prostate volume and prostate-specific antigen was 90.8% and 82.5%, respectively. At 1 month, mean Q(max) increased from 7.7 +/- 2.3 to 25.8 +/- 10.1 mL/s (P <or=.001), mean PVR decreased from 171.3 +/- 126.3 to 41.6 +/- 45.7 mL (P <or=.001), and mean international prostate symptom score improved from 17.3 +/- 6.7 to 6.6 +/- 3.4 (P <or=.001). These improvements were sustained throughout a 12-month follow-up period. Temporary irritative symptoms were evident in 34.6% and stress urinary incontinence in 9%, both of which were self-limited on medical treatment and Kegel exercises, respectively. Only 1 patient with pancytopenia required blood transfusion and there was no case for transurethral resection syndrome. CONCLUSIONS: HoLEP is a safe and an effective modern modality for the treatment of symptomatic BPH regardless of the gland size, with satisfactory clinical outcome. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Ahmed M Elshal; Ramy Mekkawy; Mahmoud Laymon; Ahmed El-Assmy; Ahmed R El-Nahas Journal: Can Urol Assoc J Date: 2015-09-09 Impact factor: 1.862
Authors: Mohammad Hout; Aaron Gurayah; Maria Camila Suarez Arbelaez; Ruben Blachman-Braun; Khushi Shah; Thomas R W Herrmann; Hemendra N Shah Journal: World J Urol Date: 2022-10-04 Impact factor: 3.661
Authors: Ahmed M Elshal; Yasser Eldemerdash; Ramy Mekkawy; Diaa-Eldin Taha; Mahmoud Laymon; Ahmed R El-Nahas; Ahmed El-Assmy Journal: Arab J Urol Date: 2016-03-17